Curated News
By: NewsRamp Editorial Staff
October 02, 2025
Quantum BioPharma's MS Drug Advances with Key Study Results
TLDR
- Quantum BioPharma's positive toxicity results for Lucid-MS position it as a first-in-class MS treatment, creating significant market advantage ahead of Phase 2 trials.
- Quantum BioPharma completed 90-day oral toxicity and toxicokinetic studies for Lucid-MS, supporting its IND application to the FDA for Phase 2 clinical trials.
- Lucid-MS represents a potential breakthrough for MS patients by targeting demyelination, offering hope for improved quality of life through novel treatment approaches.
- Quantum BioPharma's Lucid-MS is a patented chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis.
Impact - Why it Matters
This development represents a potential breakthrough for the approximately 2.8 million people worldwide living with Multiple Sclerosis. Current MS treatments primarily focus on managing symptoms and reducing relapse rates, but Lucid-MS targets the fundamental cause of the disease—demyelination. If successful in clinical trials, this could become the first treatment capable of reversing nerve damage in MS patients, potentially restoring neurological function and dramatically improving quality of life. For the biopharmaceutical industry, it demonstrates progress in developing treatments for neurodegenerative conditions that have historically been difficult to treat effectively.
Summary
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has achieved a significant milestone in its development of Lucid-21-302, known as Lucid-MS, a potential breakthrough treatment for Multiple Sclerosis. The company announced it has received final reports from its 90-day oral toxicity and toxicokinetic studies, which will support its upcoming Investigational New Drug (IND) application to the U.S. Food and Drug Administration. This crucial step paves the way for a Phase 2 clinical trial and represents a major advancement for what could become a first-in-class treatment specifically targeting demyelination—the underlying mechanism of Multiple Sclerosis where the protective covering of nerve fibers deteriorates.
Through its wholly owned subsidiary Lucid Psycheceuticals Inc., Quantum BioPharma is focused on developing innovative treatments for challenging neurodegenerative and metabolic disorders. Lucid-MS has demonstrated promising results in preclinical models, showing the ability to prevent and reverse myelin degradation. The company maintains a diverse portfolio that includes its unbuzzd(TM) product, which has been spun out to Unbuzzd Wellness Inc., with Quantum BioPharma retaining 20.11% ownership and significant royalty agreements. The company also maintains strategic investments through its FSD Strategic Investments Inc. subsidiary, representing loans secured by property assets.
For investors and stakeholders seeking comprehensive information, the latest updates relating to QNTM are available through the company's newsroom at the InvestorBrandNetwork. This platform provides access to detailed corporate communications and development progress. The announcement was distributed through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio that focuses on biotechnology and life sciences sectors, ensuring broad dissemination to investors, journalists, and the general public through various distribution channels including wire services, editorial syndication, and social media networks.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma's MS Drug Advances with Key Study Results
